Cartesian Therapeutics (RNAC) Share-based Compensation (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Share-based Compensation of $2.4 million for Q1 2026, down 3.39% year-over-year from $2.5 million in Q1 2025, and up 132.17% quarter-over-quarter from -$7.5 million in Q4 2025.
Cartesian Therapeutics (RNAC) Share-based Compensation (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Share-based Compensation for 12 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 3.39% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $759000.0 (down 90.09% YoY), while the FY2025 annual figure was $844000.0, down 87.18% from the prior year.
- Share-based Compensation improved to $2.4 million in Q1 2026 per RNAC's latest filing, from -$7.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.8 million in Q2 2023 and bottomed at -$7.5 million in Q4 2025.
- Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $2.3 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 173.0% — and 2025, when it slumped 503.91%.
- Cartesian Therapeutics' Share-based Compensation stood at $2.3 million in 2022, then sank by 402.28% to -$6.9 million in 2023, then soared by 127.11% to $1.9 million in 2024, then plunged by 503.91% to -$7.5 million in 2025, then surged by 132.17% to $2.4 million in 2026.
- Business Quant data shows RNAC's Share-based Compensation at $2.4 million in Q1 2026, -$7.5 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.08 Mn |
| Jun 30, 2026 | 2.08 Mn |
| Mar 31, 2026 | 2.42 Mn |
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | -7.53 Mn |
| Dec 31, 2025 | -7.53 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.43 Mn |